Genmab — December 2015
-
Det er 2 forskellige speakers (Torben og en Ajai Chari) så går ud fra at det blot bliver 2 hurtige præsentationer af resultaterne
-
-
-
Genmab er hurtige: De har lagt hele præsentationen op nu: http://files.shareholder.com/downloads/AMDA-KPIBN/961210947x0x864981/A4C55FC0-9A6D-4054-994A-E55638CEA4A0/Plesner_GEN503_Presentation_ASH2015_12-6-15.pdf
-
Så er det Pomalyst tid
-
Response rates with Dara Len dex 88% -suggests use of dex and fears of abrogating immune effects of Dara are not real #ASH15 #mmsm #immunonc
-
-
Svært at nå at følge med.
-
Jeg syntes Pomalyst data ser ekstremt dårlige ud? De er da noget dårlige end Revlimid?
-
der var kun 3 CR+sCR - og meget mærkværdigt havde 2 af disse relapse efter 12-18 måneder?
-
PFS data etc. er også noget dårligere end Revlimid.
-
pt. er jeg glad for at det er revlimid man har satset på i phase III
-
Pomalyst dataene undrer... Jeg har dog ikke set på patienter om de var ekstra syge her. Syntes dog det er bekymrende at 2 ud af 3 som havde CR+sCR havde hurtig relapse
-
Both daratumumab and pembroluzumsb with lenalidomide were really impressive in terms of response depth
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind